BioNTech SE - ADR

-6.04 (-3.05%)
Products, Expansion, Regulatory

Pfizer And Biontech Propose Expansion Of Pivotal Covid-19 Vaccine Trial

Published: 09/12/2020 15:06 GMT
BioNTech SE - ADR (BNTX) - Pfizer and Biontech Propose Expansion of Pivotal Covid-19 Vaccine Trial.
Pfizer - Submitted Amended Protocol to U.S. FDA to Expand Enrollment of Phase 3 Pivotal Covid-19 Vaccine Trial to Up to About 44,000 Participants.
Pfizer - Enrollment in Trial Has Been Proceeding As Planned and Company Expects to Reach Its Initial Target of Up to 30,000 Participants Next Week.
Pfizer - Proposed Expansion Would Allow the Companies to Further Increase Trial Population Diversity.
Pfizer - Companies Continue to Expect That a Conclusive Readout on Efficacy is Likely by the End of October.